Akeso Grants Commercialization Rights for Hypercholesterolemia Drug to Hubei Jumpcan Pharmaceutical Unit

MT Newswires Live

02/03

Akeso (HKG:9926) units Akeso Biopharma and AD Pharmaceuticals granted JumpCan Pharmaceutical exclusive commercialization rights for the ebronucimab injection within China, according to a Tuesday Hong Kong bourse filing.

JumpCan Pharmaceutical, a unit of Hubei Jumpcan Pharmaceutical's (SHA:600566), will commercialize and sell the product in China, excluding Hong Kong, the Macao Special Administrative Region, and Taiwan.

Akeso Biopharma and AD Pharmaceuticals will receive a license fee of 80 million yuan under the agreement, along with milestone payments of up to 10 million yuan, from JumpCan Pharmaceutical.

The drug is for the treatment of primary hypercholesterolemia and mixed hyperlipidemia.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2608187904"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608187904\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608187904?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 21:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608187904","market":"us","top_or_hot":-1,"title":"Akeso Grants Commercialization Rights for Hypercholesterolemia Drug to Hubei Jumpcan Pharmaceutical Unit","media":"MT Newswires Live","content":"<html><body><p> Akeso (HKG:9926) units Akeso Biopharma and AD Pharmaceuticals granted JumpCan Pharmaceutical exclusive commercialization rights for the ebronucimab injection within China, according to a Tuesday Hong Kong bourse filing.</p><p>JumpCan Pharmaceutical, a unit of <a href=\"https://laohu8.com/S/600566\">Hubei Jumpcan</a> Pharmaceutical's (SHA:600566), will commercialize and sell the product in China, excluding Hong Kong, the Macao Special Administrative Region, and Taiwan.</p><p>Akeso Biopharma and AD Pharmaceuticals will receive a license fee of 80 million yuan under the agreement, along with milestone payments of up to 10 million yuan, from JumpCan Pharmaceutical.</p><p>The drug is for the treatment of primary hypercholesterolemia and mixed hyperlipidemia.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akeso Grants Commercialization Rights for Hypercholesterolemia Drug to Hubei Jumpcan Pharmaceutical Unit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkeso Grants Commercialization Rights for Hypercholesterolemia Drug to Hubei Jumpcan Pharmaceutical Unit\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-02-03 21:17</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Akeso (HKG:9926) units Akeso Biopharma and AD Pharmaceuticals granted JumpCan Pharmaceutical exclusive commercialization rights for the ebronucimab injection within China, according to a Tuesday Hong Kong bourse filing.</p><p>JumpCan Pharmaceutical, a unit of <a href=\"https://laohu8.com/S/600566\">Hubei Jumpcan</a> Pharmaceutical's (SHA:600566), will commercialize and sell the product in China, excluding Hong Kong, the Macao Special Administrative Region, and Taiwan.</p><p>Akeso Biopharma and AD Pharmaceuticals will receive a license fee of 80 million yuan under the agreement, along with milestone payments of up to 10 million yuan, from JumpCan Pharmaceutical.</p><p>The drug is for the treatment of primary hypercholesterolemia and mixed hyperlipidemia.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2608187904","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608187904","pubTimestamp":1770124673,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Akeso (HKG:9926) units Akeso Biopharma and AD Pharmaceuticals granted JumpCan Pharmaceutical exclusive commercialization rights for the ebronucimab injection within China, according to a Tuesday Hong ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600566":"济川药业","BK1161":"生物科技","BK0201":"可转债","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","BK0239":"医药制造","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK1574":"生物医药B类股","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU1720050803.USD":"安联全方位中国股票基金","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","BK0188":"融资融券","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","BK0012":"证金概念","BK0077":"质押式回购","BK0187":"一线龙头","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","09926":"康方生物","BK0028":"国家队","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC"},"translate_title":"康方生物授予湖北Jumpcan制药公司高胆固醇血症药物商业化权利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600566":0.9,"09926":1},"content_text":"Akeso (HKG:9926) units Akeso Biopharma and AD Pharmaceuticals granted JumpCan Pharmaceutical exclusive commercialization rights for the ebronucimab injection within China, according to a Tuesday Hong Kong bourse filing.JumpCan Pharmaceutical, a unit of Hubei Jumpcan Pharmaceutical's (SHA:600566), will commercialize and sell the product in China, excluding Hong Kong, the Macao Special Administrative Region, and Taiwan.Akeso Biopharma and AD Pharmaceuticals will receive a license fee of 80 million yuan under the agreement, along with milestone payments of up to 10 million yuan, from JumpCan Pharmaceutical.The drug is for the treatment of primary hypercholesterolemia and mixed hyperlipidemia.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}